Vimarsana
Biggest News Aggregation in the World

Douglas Maffei News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Douglas Maffei. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Douglas Maffei Today - Breaking & Trending Today

TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial - Vimarsana News

TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial

BOTHELL, Wash., & COPENHAGEN, Denmark--(BUSINESS WIRE)--Oct 22, 2023--

TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged - Vimarsana News

TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged

Media Release TIVDAK demonstrated statistically significant overall survival, progression-free survival and objective response rate compared to...

PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Surviv - Vimarsana News

PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Surviv

– Trial results to be submitted for presentation at upcoming medical meeting –BOTHELL, Wash. & TOKYO--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) and Astellas Pharma Inc. (TSE:4503) today announced positive topline results from the Phase 3 EV-302 clinical trial (also known as KEYNOTE-A39) for PADCEV® (enfortumab ved...

Seagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients Wi - Vimarsana News

Seagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients Wi

BOTHELL, Wash. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) announced today that the Phase 3 innovaTV 301 global trial in recurrent or metastatic cervical cancer patients with disease progression on or after front-line therapy who received TIVDAK® (tisotumab vedoti...

Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improve - Vimarsana News

Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improve

Company AnnouncementPhase 3 innovaTV 301 confirmatory trial met its primary endpoint of improved overall survival (OS) at predetermined, independent interim analysisTrial results to be submitted for presentation at a future medical meetingGenmab and Seagen to engage in discussions with regulatory authoritiesCOPENHAG...